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Abstract
Background
Measles vaccine (MV) may have non-specific beneficial effects for child health and particu-
larly seems to prevent respiratory infections. Streptococcus pneumoniae is the leading
cause of bacterial pneumonia among children worldwide, and nasopharyngeal colonization
precedes infection.
Objective
We investigated whether providing early MV at 18 weeks of age reduced pneumococcal col-
onization and/or density up to 9 months of age.
Method
The study was conducted in 2013–2014 in Guinea-Bissau. Pneumococcal vaccine was not
part of the vaccination program. Infants aged 18 weeks were block-randomized 2:1 to early
or no early MV; at age 9 months, all children were offered MV as per current policy. Naso-
pharyngeal swabs were taken at baseline, age 6.5 months, and age 9 months. Pneumococ-
cal density was determined by q-PCR. Prevalence ratios of pneumococcal colonization and
recent antibiotic treatment (yes/no) by age 6.5 months (PR6.5) and age 9 months (PR9) were
estimated using Poisson regression with robust variance estimates while the pneumococcal
geometric mean ratio (GMR6.5 and GMR9) was obtained using OLS regression.
Results
Analyses included 512 children; 346 early MV-children and 166 controls. At enrolment, the
pneumococcal colonization prevalence was 80% (411/512). Comparing early MV-children
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with controls, the PR6.5 was 1.02 (95%CI = 0.94–1.10), and the PR9 was 1.04 (0.96–1.12).
The GMR6.5 was 1.02 (0.55–1.89), and the GMR9 was 0.69 (0.39–1.21).
Early MV-children tended to be less frequently treated with antibiotics prior to follow up
(PR6.5 0.60 (0.34–1.05) and PR9 0.87 (0.50–1.53)). Antibiotic treatment was associated
with considerably lower colonization rates, PR6.5 0.85 (0.71–1.01) and PR9 0.66 (0.52–
0.84), as well as lower pneumococcal density, GMR6.5 0.32 (0.12–0.86) and GMR9 0.52
(0.18–1.52).
Conclusion
Early MV at age 18 weeks had no measurable effect on pneumococcal colonization preva-
lence or density. Higher consumption of antibiotics among controls may have blurred an
effect of early MV.
Trial registration
clinicaltrials.gov NCT01486355
Introduction
In a recent WHO commissioned review[1], the live attenuated measles vaccine (MV) was asso-
ciated with reduced overall child mortality[2, 3] and morbidity[4, 5] exceeding what is attrib-
utable to prevention of measles infection. This indicates non-specific effects (NSEs) of the
vaccine. A Guinean randomized trial[4] and a register-based Danish study[6] both found that
MV was associated with significantly fewer hospital admissions with respiratory infections
when comparing measles-vaccinated children with controls whose most recent vaccination
was DTP-HepB-Hib-OPV-3 and DTP-Hib-IPV-3, respectively.
A recent observational study[7] from The Gambia found that MV and yellow fever-vaccine
(YF) co-administered at age 9 months reduced nasopharyngeal (NP) carriage of Streptococcus
Pneumoniae (pneumococci) by 75% (OR 0.25 (0.07–0.90)) when comparing carriage status 4
weeks after vaccination with before.
Pneumonia is the single largest killer of children<5 years worldwide with more than 95% of
cases occurring in low-income countries[8]. The most frequent bacterial cause is pneumococci.
Globally, pneumococci are estimated to cause 11% of all deaths among children <5 years
with 90% of fatalities due to pneumonia[9]. Pneumococcal carriage is common among chil-
dren in low-income countries from an early age[10, 11] and may be asymptomatic, but is also
a prerequisite for pneumococcal disease development[12].
We hypothesized that MV decreases respiratory infections with S. Pneumoniae through an
effect on the nasopharyngeal colonization. Thus, within an ongoing randomized controlled
trial (RCT) of early MV among infants in Guinea-Bissau, we investigated whether MV reduced
pneumococcal colonization and/or -density.
Materials and methods
Study setting
Since 1978, the Bandim Health Project (BHP) has maintained a health and demographic sur-
veillance system (HDSS) currently covering more than 100,000 individuals in 6 suburbs in the
Measles vaccine and pneumococcal colonization
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capital of Bissau, Guinea-Bissau. Through monthly home visits newborns are identified and
followed with trimonthly home visits until 3 years of age to register growth, morbidity, vacci-
nations and vital status. At the initial registration, each child is given a unique ID number to
facilitate linkage between all BHP registers.
Main early MV trial
The present pneumococcal study (MVPneumo) was nested within a RCT conducted within
the BHP urban study area from 2011 to 2015, aiming at investigating the effect of early vs. no
early MV at 18 weeks of age on overall mortality until age 5 years (MVUrban). All children
were offered the recommended MV at age 9 months. Pneumococcal conjugate vaccine (PCV)
had not been implemented in Guinea-Bissau when MVPneumo was conducted. There were
no reported measles cases throughout the duration of the study.
Inclusion criteria in the MVUrban trial were receipt of the third dose of the pentavalent
vaccine (DTP-HepB-Hib-3) at least 4 weeks before enrolment, and age below 7 months.
Through home visits, eligible children were invited for inclusion at one of the three health cen-
ters in the HDSS study area. Here, children underwent a clinical examination by a physician
and had anthropometric values measured. Severely sick children in need of hospitalization,
malnourished children (defined as a mid-upper-arm circumference less than 115 mm) and
children with severe malformations were excluded.
Provided informed oral and written consent from a parent/guardian was obtained, children
were block-randomized 2:1 stratified by sex to early or no early MV at age 18 weeks. Parents
picked a folded lot from a sex-specific envelope containing 24 lots, 2/3 of the lots assigned the
child to the intervention group (early MV), 1/3 of the lots assigned the child to the control
group (no early MV). Twins of the same sex were allocated to the same treatment to avoid con-
fusion. Children randomized to early MV received a single dose of 0.5 ml MV (Edmonston-
Zagreb strain, Serum Institute of India, Pune, India) as a subcutaneous injection in the shoul-
der region. No placebo was given, since mothers could get the false impression that their child
was vaccinated against measles and therefore abstain from the recommended 9 months MV if
they travelled or moved from the BHP study area.
The pneumococcal sub-study
From August 2013 to January 2014, children enrolled in MVUrban were invited to participate
in MVPneumo. Provided informed consent, three nasopharyngeal swabs (NPS) were sched-
uled to be taken: At enrolment, 2 months later (approximately age 6.5 months), and at 9
months of age. Children older than 6 months at enrolment were not followed up before age 9
months. The last child was followed up by June 2014.
Children and their caretakers were visited at home by field assistants and invited to the
health center for NPS.
At the health center a questionnaire was completed comprising health status of the child,
anthropometric values were measured, and the nasopharynx was swabbed. Information on
recent medication of the child (within last three days) and the mother (within last week) was
registered (antimalarials, antibiotics, pain killers, and others; if possible, the specific name(s) of
medicine taken was registered).
At 9 months of age, the NPS was taken immediately before measles vaccination.
MVPneumo staff were blinded to the randomization status of children since randomization
took place in a separate room after the first NPS was obtained. Moreover, randomization status
was not registered on the health card of the child so the staff remained blinded at follow up
visits.
Measles vaccine and pneumococcal colonization
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All procedures of MVUrban and MVPneumo were carried out by employees of the BHP,
including doctors, nurses and trained assistants.
Nasopharyngeal swabs. NPS procedures followed a protocol based on WHO recommen-
dations[13]. A flexible swab (Minitip Flocked Swab, Copan, Brescia, Italy) was inserted to the
level of the posterior nasopharynx[13, 14] and rotated. If resistance was met before this point,
the swab was discarded and a new attempt made through the other nostril. If second attempt
failed, no specimen was obtained.
The swab was then rotated in 0.5 ml 0.9% saline and a 0.25 ml aliquot of this specimen solu-
tion was transferred by a 1 ml single-use Pasteur-pipette to a cryotube containing 100 μl DNA
stabilizing transport medium (AssayAssure, Sierra Molecular, Sonora, CA, USA) and shaken.
Samples were temporarily contained in a cold box until frozen at minimum -20˚C within a
maximum of 7 hours. All equipment was disinfected twice with 70% ethanol between swab-
bing procedures and the staff wore disposable gloves within the process.
Detection of S. pneumoniae by quantitative PCR. Genomic DNA was extracted from
125 μl of the NPS specimen solution using the FastDNA™ spin kit for soil (MPBiomedicals,
LLC, Santa Ana, CA, USA) with elution into 100 μl. The number of pneumococci detected
from 5 μl DNA-extraction was determined using a quantitative real-time PCR (q-PCR) detect-
ing the autolysin gene (lytA) as described by the US CDC[15]. Furthermore, an internal ampli-
fication control was constructed as previously described[16]. PCR was performed in a 50 μl
final volume with thermocycling conducted on an ABI 7500 real-time PCR instrument. A
standard curve was constructed from 10-fold dilutions of purified S. Pneumoniae DNA in TE
buffer containing calf-thymus DNA as stabilizer/carrier DNA[16]. Results were analysed using
7500 Software v2.3, Applied Biosystems. In case of absence of internal control the sample was
re-analysed. All analyses were conducted at Statens Serum Institut in Denmark (PCR methods
described in detail in the S1 Appendix). Laboratory technicians were blinded to the randomi-
zation status of children.
Statistical analysis
All analyses were based on intention-to-treat. One mother agreed to participate in MVUrban
but refused to let her child be vaccinated when randomized to early MV; however, estimates
from per-protocol analyses were similar since reclassification of one observation did not alter
the findings.
Categorical variables describing pneumococcal colonization status (No/Yes), were defined
based on the presence of pneumococcal DNA detected by q-PCR. In addition, a categorical
variable describing recent antibiotic treatment of the child (No/Yes) was defined. The analysis
of the effect of antibiotics on pneumococcal colonization and density was not originally
planned but was conducted after discovering that early MV children had a markedly lower
consumption of antibiotics than controls.
The primary outcomes, pneumococcal prevalence ratios at 6.5 and 9 months of age (PR6.5
and PR9), were estimated using Poisson regression with robust variance estimation[17]. The
secondary outcomes, geometric mean ratios (GMR6.5 and GMR9) of pneumococcal density
according to MV status, were computed for colonized children. We applied linear ordinary
least square (OLS) regression, using the logarithmic transformed density as variable.
Stratified analyses. In the protocol it was pre-specified that all analyses would be stratified
by sex.
A previous study suggested that receiving oral polio vaccine (OPV) during campaigns prior
to early MV is associated with a less beneficial effect of early MV[18], hence, we stratified the
present data on whether children had participated in OPV campaigns prior to enrolment or not.
Measles vaccine and pneumococcal colonization
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Moreover, in a Guinean study[4] investigating the effect of early MV on hospital admis-
sions, the beneficial effect was strongest among children vaccinated in the dry season (Dec-
May). Hence, we also stratified by season at enrolment.
Stratification by receipt of OPV and season were not pre-specified in the protocol, but
based on the above mentioned findings.
Sensitivity analysis. Lower pneumococcal density values are related to increased mea-
surement uncertainty, and only single assessments were done. Nonetheless, exploring cut off
values of density ranging from 100 through 2,000 genome equivalents did not modify the esti-
mate of the MV effect on colonization or density. Thus, a cut off was not implemented in the
analyses.
All estimates are reported with 95% confidence intervals. Analyses were performed in Stata
version 12.0 (StataCorp, College Station, TX, USA).
Sample size. We intended to include 420 early MV-children and 210 controls based on
detecting a 10% reduction of pneumococcal colonization among MV-children, from 85% to
75%, with a power of 80% and significance level α = 0.05.
Ethical considerations
The early MV trial and the pneumococcal sub-study were approved by the Ethical Committee
in Guinea-Bissau (CNES-2013-031). The Developing-Country Committee of The National
Committee on Health Research Ethics, Denmark, gave its consultative approval. All partici-
pants gave their informed consent. MVUrban is registered at clinicaltrials.gov NCT01486355
Results
Study population
Within the pneumococcal study period, 703 children (94% of all eligible) were enrolled in the
MVUrban trial. Of these, 651 children (93% of inclusions) were enrolled in the MVPneumo
study. At age 6.5 and 9 months, 515 (79%) and 529 (81%) children were followed up with a
NPS, respectively (see Fig 1. Flowchart of the study). Specimens from 512 children having a
successful swab available from both inclusion and 9 months follow up were analyzed (17 sam-
ples were lost). Of these, 410 children (80%) also had the 6.5 months swab available and ana-
lyzed. Children lost to follow-up differed on a number of factors, e.g. they were older and
came from more deprived groups (data not shown). Losses to follow-up were comparable in
the early MV group (20% at 6 months, 18% at 9 months) and the no early MV group (23% at 6
months, 20% at 9 months).
Of the 512 children analyzed, 346 (68%) were randomized to early MV and 166 (32%) to no
early MV. Enrolment in rainy season (Jun-Nov) comprised 65% of children, and 52% of chil-
dren received OPV during national campaigns before enrolment (Table 1); no children
received campaign vaccines between enrolment and age 9 months. Randomization resulted in
comparable groups according to all background factors (Table 1).
At enrolment, 80% of children were colonized with pneumococci (411/512, Table 1). At age
6.5 and 9 months, 87% and 85% of children were colonized, respectively. Using Pearson’s test
of correlation, log-transformed density values were uncorrelated between inclusion and 6.5
months (ρ = 0.09, p = 0.10), whereas some correlation was found between inclusion and 9
months (ρ = 0.18, p<0.01).
Three health professionals obtained NPSs; controlling for investigator did not impact the
assessment of early MV’s effect on colonization status or density (data not shown).
Measles vaccine and pneumococcal colonization
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Effect of early MV on pneumococcal colonization and density
The prevalence of pneumococci was similar between early MV-children and controls at age
6.5 and 9 months, PR6.5 1.02 (0.94–1.10) and PR9 1.04 (0.96–1.12), respectively (Table 2). No
sex-differential effect was observed.
No effect of MV was found on pneumococcal density at 6.5 months overall, GMR6.5 1.02
(0.55–1.89). At age 9 months, the overall GMR9 was 0.69 (0.39–1.21) (Table 2). Again, no sex-
differential effect was observed.
Recent antibiotic treatment
At both follow up visits (Table 3) early MV-children were less frequently treated with antibiot-
ics within the last three days compared with controls, PR6.5 being 0.60 (0.34–1.05) and PR9
0.87 (0.50–1.53).
Overall, recent antibiotic treatment was associated with lower colonization rates, PR6.5 0.85
(0.71–1.01) and PR9 0.66 (0.52–0.84), and decreased density, GMR6.5 0.32 (0.12–0.86) and
GMR9 0.52 (0.18–1.52) (Table 4). Predominantly, β-lactam antibiotics such as Amoxicillin,
Ampicillin, and Augmentin were used.
Stratified analyses: Receipt of oral polio vaccine and season
Stratification by receipt vs. no receipt of OPV during campaigns before enrolment showed no
effect regarding colonization prevalence (S1 Table). At age 6.5 months, pneumococcal density
Fig 1. Flowchart of MVPneumo.
https://doi.org/10.1371/journal.pone.0177547.g001
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Table 1. Comparison of baseline characteristics of the two randomization groups.
Investigated variables, N (% of total number) % (No.) P
Early MV No early MV
N = 346 (68%) N = 166 (32%)
Demographic factors
Age at inclusion (days), median (IQR) 145 (140–158) 147 (140–158)
Boys, N = 281 (55) 55% (189) 55% (92)
Girls, N = 231 (45) 45% (157) 45% (74) 0.87
District
Bandim, N = 214 (42) 41% (143) 43% (71)
Belem, N = 74 (14) 14% (49) 15% (25)
Cuntum, N = 224 (44) 45% (154) 42% (70) 0.88
Ethnicity
Papel, N = 144 (28) 29% (102) 25% (42)
Fula, N = 81 (16) 15% (51) 18% (30)
Manjaco, N = 68 (13) 14% (48) 12% (20)
Other ethnicities, N = 219 (43) 42% (145) 45% (74) 0.58
Socioeconomic status
The mother is literate, N = 370 (72) 72% (248) 73% (122)
The mother is illiterate, N = 142 (28) 28% (98) 27% (44) 0.67
Civil status
Unmarried mother, N = 200 (39) 39% (135) 39% (65)
Mother married, N = 308 (60) 60% (208) 60% (100)
Mother divorced/widow, N = 4 (1) 1% (3) 1% (1) 0.95
The household has
Refrigerator, N = 124 (24) 22% (77) 28% (47) 0.13
Television, N = 246 (48) 49% (171) 45% (75) 0.37
Piped water, N = 140 (27) 25% (88) 31% (52) 0.16
Pigs in the household, N = 177 (35) 36% (123) 32% (54) 0.50
Anthropometric values
Mean (SD) height (cm) 62.9 (2.7) 63.1 (2.9) 0.32
Mean (SD) weight (kg) 7.2 (1.00) 7.2 (1.01) 0.92
Mean (SD) mid upper arm circumference (mm) [NA = 2] 142 (12) 141 (12) 0.54
Health status of the child
Ill at enrolment, N = 40 (8) 8% (29) 7% (11) 0.49
Mean (SD) temperature (˚C) [NA = 2] (0.4) 36.6 (0.4)
Normal lung auscultation, N = 475 (93) 92% (319) 94% (156) 0.47
Bronchitis, N = 20 (4) 4% (14) 4% (6) 0.81
Pneumonia, N = 16 (3) 3% (12) 2% (4) 0.52
Wheezing, ever, N = 123 (24) 25% (88) 21% (35) 0.28
Coughing at enrolment, N = 208 (41) [NA = 109] 40% (139) 41%(69) 0.76
Coughing within the last 4 weeks, N = 336 (66) 65% (224) 67% (112) 0.54
Visible nasal secretions, N = 31 (6) [NA = 31] 7% (24) 4% (7) 0.32
Diarrhea, N = 51 (10) 10% (33) 11% (18) 0.64
Child is breastfed, N = 505 (99) 99% (343) 98% (162) 0.16
Mother has history of measles infection, [NA = 4]
– Yes, N = 111 (22)
– No, N = 220 (43)
– Do not know, N = 177 (35)
22% (76)
43% (150)
34% (116)
21% (35)
42% (70)
37% (61)
0.82
Number of prior hospital admissions, median (IQR) 1 (1–1) 1 (1–1)
(Continued )
Measles vaccine and pneumococcal colonization
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tended to be reduced among early MV-children who had not participated in OPV campaigns
prior to enrolment (GMR6.5 NO OPV 0.50 (0.21–1.23), whereas the opposite tendency was seen
among early MV-children who did receive campaign OPV before enrolment, (GMR6.5 OPV
1.83 (0.78–4.28). Hence, there was a significant interaction between early MV and campaign
OPV before enrolment (p = 0.04). This association was not maintained at age 9 months
Table 1. (Continued)
Investigated variables, N (% of total number) % (No.) P
Early MV No early MV
N = 346 (68%) N = 166 (32%)
Hospitalized at all before inclusion, N = 27 (5) 6% (20) 4% (7) 0.46
Child medicated within the past 3 days, N = 107 (21) 21% (74) 20% (33) 0.69
Child medicated with antibiotics within the past 3 days, N = 50 (10) [NA = 1] 10% (35) 9% (15) 0.73
Vaccination history
Participated in OPV campaign prior to enrolment, N = 266 (52) 50% (172) 57% (94) 0.14
Has a BCG scar, N = 472 (92) 92% (319) 92% (153) 0.99
Known risk factors for pneumonia/pneumococcal carriagea
No of people/bed incl. the child, median (IQR) [NA = 1] 3 (2–3) 3 (2–3)
No of people/room incl. the child, median (IQR) 4 (3–5) 4 (3–5)
Child is breastfed by a mother treated with antibiotics within the past week, N = 9 (2) [NA = 4] 1% (4) 3% (5) 0.31
Enrolled in rainy season (June 1 –Nov 30), N = 331 (65)
Enrolled in dry season, (Dec1 –May 31), N = 181 (35)
65% (226)
35% (120)
63% (105)
37% (61)
0.65
The child is exposed to indoor fire smoke, N = 51 (10) [NA = 16]b 11% (38) 8% (14) 0.37
Pneumococcal colonization/density
Colonized with pneumococci, N = 411 (80%) 80% (278) 80% (133) 0.95
Pneumococcal density, mean (SD) 47145 (143770) 66760 (226327) 0.24
Geometric mean = 3968 3699 4596 0.48
Geometric mean ratio (95% CI)c 0.80 (0.45–1.45) 1.00 (ref)
a one single parent reported cigarette smoking;
binformation on indoor fire smoke was obtained from self-reports at 9 months of age, however, we assume that no changes in behavior related to heating/
cooking has taken place since enrolment;
c raw unadjusted mean ratio.
https://doi.org/10.1371/journal.pone.0177547.t001
Table 2. Association of early measles vaccine (MV) and pneumococcal colonization and density.
Pneumococcal colonization Pneumococcal density
Early MV No early MV PRa of colonization Geometric mean GMRa (95% CI)
6.5 MONTHS N colonized/N N colonized/N (95% CI) Early MV/no early MV Early MV/no early MV
Missing NA = [70] NA = [32]
Overall; N = 410 241/276 (87%) 115/134 (86%) 1.02 (0.94–1.10) 2885/2820 1.02 (0.55–1.89)
Boys; N = 225 132/153 (86%) 60/72 (83%) 1.04 (0.92–1.17) 2338/2876 0.81 (0.34–1.94)
Girls; N = 185 109/123 (89%) 55/62 (89%) 1.00 (0.90–1.11) 3721/2760 1.35 (0.56–3.22)
9 MONTHS
Overall; N = 512 298/346 (86%) 138/166 (83%) 1.04 (0.96–1.12) 2117/3078 0.69 (0.39–1.21)
Boys; N = 281 161/189 (85%) 77/92 (84%) 1.02 (0.91–1.13) 1727/3017 0.57 (0.27–1.23)
Girls; N = 231 137/157 (87%) 61/74 (82%) 1.06 (0.94–1.20) 2691/3157 0.85 (0.37–1.95)
a Early MV versus no early MV.
https://doi.org/10.1371/journal.pone.0177547.t002
Measles vaccine and pneumococcal colonization
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(GMR9 NO OPV = 0.58 (0.26–1.30), GMR9 OPV = 0.83 (0.38–1.82), test for interaction p = 0.53),
possibly due to the effect of later OPV campaigns, as subsequent OPV campaigns tended to
blur the difference between those who had and had not received campaign OPV before enrol-
ment (data not shown).
The analysis by season of enrolment did not show any significant differences between chil-
dren enrolled in the rainy and dry season, respectively (S2 Table).
Discussion
We found no overall effect of early MV on pneumococcal colonization or pneumococcal den-
sity at age 6.5 or 9 months.
Strengths and limitations
The randomization ensured that background variables were balanced between randomization
groups (Table 1).
Post randomization imbalances—Antibiotic treatment. In post hoc analyses we found
that early MV-children were less frequently treated with antibiotics at follow up. This is in line
with the findings of a morbidity subgroup study within the main trial, which found that early
MV was associated with a reduced risk of morbidity from 4 to 9 months of age[5]. Thus, as
anticipated, early MV may indeed have had beneficial non-specific effects on overall health.
This, however, could have large implications for the outcome of the present trial, because
recent antibiotic treatment was associated with fewer colonized children and lower pneumo-
coccal density. The association between antibiotic treatment and pneumococcal colonization
and density is well-known; transient reducing effects on overall pneumococcal colonization
Table 3. Association between early measles vaccine (MV) and subsequent antibiotic treatment.
Early MV No early MV PR of antibiotic treatment in children who
Recently treated Recently treated received early MV vs. no early MV (95% CI)
6.5 MONTHS (N = 512) 7% 12% 0.61 (0.35–1.05)
Recently treated (N = 45) (25/346 [NA = 53]) (20/166 [NA = 24])
9 MONTHS (N = 512) 9% 10% 0.87 (0.50–1.53)
Recently treated (N = 48) (31/346 [NA = 4]) (17/166 [NA = 2])
NA = missing information on recent intake of antibiotics
https://doi.org/10.1371/journal.pone.0177547.t003
Table 4. Association between recent antibiotic treatment and pneumococcal colonization and density.
Pneumococcal colonization Pneumococcal density
Recently treated Not recently treated PR of colonization Treated/not treated
6.5 MONTHS Colonized/N Colonized/N (95% CI) Geometric mean GMR (95% CI)
Overall; N = 512 73% 82%
[NA = 102]* (33/45 [NA = 1]) (320/390 [NA = 28]) 0.85 (0.71–1.01) 1022/3201 0.32 (0.12–0.85)
9 MONTHS
Overall; N = 512 58% 88%
[NA = 0]** (28/48) (403/458) 0.66 (0.52–0.84) 1301/2530 0.51 (0.18–1.49)
NA = missing information on pneumococcal status;
*additionally, 76 children miss information on antibiotic treatment at age 6.5 months;
**additionally, 6 children miss information on antibiotic treatment at age 9 months.
https://doi.org/10.1371/journal.pone.0177547.t004
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have been shown for β-lactam antibiotics [19, 20] and macrolides [21] when measured by cul-
ture, as well as for antimicrobials in general when measured with PCR [22, 23]. Thus, a protec-
tive effect of MV on pneumococcal colonization could have been masked by antibiotic
treatment being overrepresented among controls.
However, we chose not to adjust for antibiotic treatment in the analyses, because bias
would be introduced when adjusting or stratifying for a post randomization variable associated
with a prior intervention[24] (so-called inconsistent mediation[25]).
Unfortunately, antibiotic treatment of children was only registered if taken within three
days prior to examination so we are unsure if this observation reflects differences in the overall
consumption of antibiotics in each group. Also, no objective measure of antibiotic activity in a
child was assessed. Information on antibiotic intake relied solely on reporting by mothers.
They do not necessarily know whether a given medication prescribed by the doctor is an anti-
biotic and they might not remember the exact name of the medicine. At the 6.5 months visit,
however, the information was also based on seeing the medicine packaging by the home visit-
ing nurse, increasing the reliability of the information at this visit.
Sample size and loss to follow up. The sample size was intended to include minimum
420 early MV-children and 210 controls. However, only samples from 346 and 166 children
(early MV/no early MV) were analyzed resulting in a statistical power to show a significant dif-
ference of 74% in contrast to the anticipated power of 80%.
Additionally, 21% and 19% of enrolled children were lost to follow up at 6.5 and 9 months
of age, respectively, and comprised a predominance of the less advantaged children (data not
shown), which may reduce the generalizability of the findings. However, since loss to follow-
up was evenly distributed between randomization groups we do not believe it affected the esti-
mated early MV effect.
Consistency with other studies
Pneumococcal carriage rates. Pneumococcal carriage rates among infants in Guinea-Bis-
sau have not previously been investigated, but the observed rates are consistent with reports
from other West African countries: The Gambia[11] (80% prevalence by the age of 13 weeks),
Burkina Faso[26] (73% among 6–11 months old), and Nigeria[27] (approximately 90% among
6–9 months old), before the introduction of PCV, which took place in 2009, 2013, and 2014,
respectively[28].
Effect of yellow fever vaccine and oral polio vaccine. In the Gambian before-after study
[7] a 75% reduction of NP pneumococcal carriage (OR 0.25 (0.07–0.90)) was seen after co-
administration of measles and yellow fever vaccine at age 9 months. The effect was strongest
within 4 weeks following vaccination, and non-significant >4 weeks after. In the present
study, at least 2 months passed from enrolment to first follow up because we aimed at explor-
ing longer-term effects so a transient effect of MV might have been missed.
Additionally, the YF vaccine could have beneficial NSEs like other live vaccines such as
MV, BCG[29], smallpox[30], and OPV[31–33]. In the present study, we investigated the effect
of early MV alone since YF vaccine is only recommended at age 9 months.
Two national OPV campaigns were conducted within the study period (Table 1). Data
from a previous trial suggest that receiving OPV in campaigns prior to early MV is associated
with a less beneficial effect of early MV[18]. We saw the same tendency in the present study
(S1 Table), with a more beneficial effect of early MV on pneumococcal density in children
who had not received campaign-OPV before enrolment.
Our data did not support a stronger beneficial effect of early MV among children enrolled
in dry season as indicated by a previous Guinean trial[4] (S2 Table).
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Interpretation
Previous Danish and Guinean studies have observed beneficial NSEs of MV on respiratory
morbidity[4, 6]. Supported by the Gambian before-after study we hypothesized that this could
be mediated via an effect on pneumococcal colonization. This hypothesis was not confirmed.
There are several potential explanations for that.
First, preponderance of antibiotic treatment in the control group may have masked an
effect of early MV on pneumococcal colonization along with a possibly blurring effect of the
national OPV-campaigns. WHO has called for more studies into non-specific effects of vac-
cines, and particularly encouraged more RCTs[34]. The present study is a good example of
the potential caveats in conducting RCTs. In real life, if the intervention changes their post-
randomization health, children in a randomized trials can only be considered “randomized”
on the day of enrolment. The present study indicated that early MV-children may have had
less antibiotics (i.e. a beneficial non-specific effect of early MV). This again may have affected
the outcome of the study, pneumococcal colonization. Importantly, if one tries to adjust for
such post-randomization imbalances additional bias is potentially introduced. Furthermore,
there are now many indications that health interventions interact [35, 36], and thus interven-
tions occurring both before and after the RCT intervention, e.g., OPV campaigns, may blur
the effect of the RCT intervention in unforeseen ways. This calls for more advanced epidemi-
ological tools to evaluate the real-life effect of health interventions in the context of other
interventions.
Secondly, viruses are also important causes of respiratory infections in the first years of life
[37], e.g. RSV[38] and influenza virus [39]. Indeed, MV has been associated with a reduced
rate of hospital contacts with laboratory-confirmed RSV infections in Denmark [40]. Viral
infections paving the way for invasive bacterial infection is well-documented [41, 42], includ-
ing promotion of pneumococci by influenza virus.[43, 44] Hence, MV may indirectly decrease
bacterial co-/superinfection by inducing immunity against heterologous viruses rather than
changing the NP bacterial colonization per se.
Moreover, the nasopharynx is dynamic, with several potentially disease-causing microor-
ganisms constituting a commensal ecosystem with competition and promotion species in-
between. Hence, more comprehensive mapping of the entire microbial flora and more fre-
quent swabbing immediately following MV would strengthen the investigation of NSEs on
microbial carriage.
In conclusion, the present study cannot confirm or refute previous observations of a benefi-
cial effect of MV on pneumococcal colonization nor on density.
The association of MV and reduced respiratory morbidity reported in previous studies calls
for further investigations with early and frequent sampling allowing for detailed surveys of
pathogens causing respiratory disease in early childhood, including both viruses and bacteria.
The present study may serve as a baseline for future evaluation of the impact of PCV-13 that
was introduced in Guinea-Bissau in 2015.
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